TL;DR
This study identifies elevated arginase activity in myeloid cells within lung tumors as a key mechanism of immune suppression. Inhibiting this arginase activity in a mouse model of lung cancer led to significant tumor regression by restoring anti-tumor immunity, suggesting arginase as a promising therapeutic target for non-small cell lung cancer (NSCLC).
What Problem Does This Paper Address?
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, and while immunotherapies like PD-1/PD-L1 blockade have shown promise, their response rates are limited, suggesting other immune evasion mechanisms are at play. One such mechanism is metabolic deregulation within the tumor microenvironment, which can hinder anti-tumor immune responses. Arginine, a crucial amino acid for T cell function, is regulated by enzymes like arginase. While arginase's role in immune suppression is known, its specific contribution to lung tumor progression and its potential as a therapeutic target in clinically relevant models were not well understood. This paper investigates whether targeting arginase activity can overcome immune suppression and promote anti-tumor immunity in NSCLC.
Methods
The researchers employed a multi-pronged approach:
- RNA Sequencing (RNA-seq): They analyzed gene expression in sorted myeloid cell populations from mouse lung adenocarcinomas to identify arginase expression patterns.
- Multiplex Immunohistochemistry (IHC): They examined arginase expression in human NSCLC tissue microarrays (TMAs) alongside markers for immune cells (CD3 for T cells, CD66b and CXCR2 for myeloid cells) to correlate arginase levels with immune cell infiltration and tumor type.
- Ex Vivo Assays: They used splenocyte cultures to assess the impact of arginine depletion and arginase inhibition on T cell function (measured by IFN-γ secretion, Granzyme B, and IL-2 production). They also investigated the suppressive effects of isolated myeloid cells (macrophages and CD11b+ cells) on T cell responses and how arginase inhibition reversed this.
- In Vivo Mouse Model: They utilized a genetically engineered mouse model (GEMM) of lung adenocarcinoma driven by KRAS<sup>G12D</sup>. This model allowed them to test the therapeutic efficacy of a novel arginase inhibitor (compound 9) on tumor growth and to analyze changes in the tumor microenvironment.
- In Vitro Cytotoxicity Assays: They tested the direct cytotoxic effect of compound 9 on various lung cancer cell lines.
Datasets
- Mouse RNA-seq Data: Data was obtained from sorted cell populations of mouse lung adenocarcinomas derived from immunocompetent genetically engineered mouse models (GEMMs). This data was previously generated and aligned to the mm9 Ensembl transcript annotation.
- Human Tissue Microarray (TMA): A TMA comprising 150 lung adenocarcinomas, 103 squamous tumors, and 54 matched normal lung tissues was used for multiplex IHC. This dataset was described as representative of the general NSCLC patient population.
- Published Single-Cell Sequencing Data: A previously published dataset of patient lung tumors was analyzed for ARG1 and ARG2 expression.
Key Insights and Ideas
- Myeloid Cells are Key Arginase Producers in Lung Tumors: The study strongly suggests that myeloid cells, particularly neutrophils and macrophages, are the primary source of elevated arginase expression in lung tumors, both in mouse models and human patients.
- Arginase Depletes Arginine, Suppressing T Cells: The research confirms that myeloid-derived suppressor cells (MDSCs) contribute to T cell suppression by depleting arginine. This creates an immunosuppressive microenvironment that hinders anti-tumor immunity.
- Arginase Inhibition Restores T Cell Function: The novel arginase inhibitor, compound 9, effectively reversed T cell suppression in ex vivo assays by restoring arginine levels and enhancing T cell effector functions like IFN-γ production.
- In Vivo Efficacy in a Relevant Model: Crucially, compound 9 demonstrated significant therapeutic efficacy in a KRAS<sup>G12D</sup> GEMM of lung adenocarcinoma, leading to tumor regression. This effect was linked to increased T cell infiltration and function within the tumor.
- Arginase as a Biomarker and Therapeutic Target: The findings highlight arginase expression as a potential biomarker for identifying tumors that might benefit from arginase inhibition, and the inhibitor itself as a promising therapeutic agent, particularly for checkpoint blockade-resistant tumors.
Key Results
- Elevated Arginase in Tumors: RNA-seq showed significantly increased Arg1 expression in macrophages and neutrophils from mouse lung tumors compared to controls. IHC confirmed elevated ARG1 expression, primarily in neutrophils, in both human lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) compared to normal lung tissue.
- Correlation with Immune Cells: Arginase expression in neutrophils (CD66b+/ARG1+) was significantly correlated with CD3+ T cell density, showing an inverse relationship, suggesting that higher arginase correlates with lower T cell infiltration.
- Arginase Inhibitor Efficacy: Compound 9 inhibited human arginase I and II with low IC50 values and was active in ex vivo assays. In the KRAS<sup>G12D</sup> GEMM, daily administration of compound 9 (30 mg/kg) led to a significant reduction in tumor volume within one week and sustained tumor growth delay over four weeks.
- Immune Microenvironment Modulation: Cpd9 treatment in the mouse model increased tumor T cell infiltration (CD3, CD4, CD8), enhanced the CD8/Foxp3 ratio, and boosted IFN-γ production by tumor-infiltrating lymphocytes.
- Lack of Direct Cytotoxicity: Compound 9 showed no direct cytotoxic activity against various lung cancer cell lines in vitro, indicating its anti-tumor effect is primarily mediated through immune modulation.
Limitations and Future Work
- Arginase 2 Role: While the study focused on arginase 1, it notes that arginase 2 was also present and its role in maintaining T cell tolerance in health and disease warrants further investigation.
- In Vitro vs. In Vivo Efficacy: The lack of direct cytotoxic activity in vitro for compound 9 suggests its therapeutic benefit is largely dependent on the in vivo immune microenvironment, which is a key finding but also implies limitations for targeting tumors with a severely compromised immune infiltrate.
- Biomarker Potential: While arginase expression can be detected by IHC, further validation is needed to establish its precise utility as a predictive biomarker for treatment response.
- Broader Application: The authors suggest investigating arginase inhibition as an immunotherapy agent in other cancer types where myeloid cells are dominant and resistant to current immunotherapies.
- Combination Therapies: The potential for combining arginase inhibitors with other immunotherapies, such as checkpoint inhibitors, is an avenue for future research, especially given the observed inverse correlation between arginase and T cell infiltration.
Summary updated